Mosquirix, the malaria candidate from GlaxoSmithKline, recently received positive feedback from regulators in Europe about the malaria prevention rates in young children who live in sub-Saharan Africa.
The positive scientific reviews came from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
"Today's scientific opinion represents a further important step towards making available for young children the world's first malaria vaccine,” Sir Andrew Witty, CEO of GSK, said. “While RTS,S on its own is not the complete answer to malaria, its use alongside those interventions currently available such as bed nets and insecticides, would provide a very meaningful contribution to controlling the impact of malaria on children in those African communities that need it the most. The work doesn't stop here and GSK remains committed to investing in R&D for malaria vaccines and treatments to find more ways to tackle this devastating disease."
Now the World Health Organization (WHO) is scheduled to determine how
this malaria candidate vaccine, the first in the world, can be applied
with other tools to stop malaria from spreading further. The WHO must also develop a policy recommendation for the vaccine as part of national immunization programs.
"Today marks a significant scientific milestone for the long-standing partnership to develop a vaccine, yet several more steps remain before a malaria vaccine might reach the young children in Africa who most need protection against this deadly human parasite,” Dr. David C. Kaslow, vice president of product development at PATH, said. “PATH will continue to work with GSK and other partners to ensure that the evidence is available, as soon as possible, to support informed decision-making on those remaining steps."